Split-Face Study of the Efficacy and Persistence of Reconstituted and Refrigerated PrabotulinumtoxinA

Temporary Greater Auricular Nerve Paresthesia After Radiofrequency Microneedling Treatment

Observations Regarding Infection Risk in Lower-Extremity Wound Healing by Second Intention

Reducing Anxiety With Art Activities During the Mohs Micrographic Surgery Waiting Period

Botulinum Toxin A Improves Supramuscular Fat Graft Retention by Enhancing Angiogenesis and Adipogenesis BACKGROUND Autologous fat grafting is commonly used for soft-tissue augmentation and reconstruction in plastic surgery. However, long-term graft retention rates are unpredictable, especially in muscle-related fat grafting. OBJECTIVE To determine whether botulinum neurotoxin type A (BoNTA) may improve supramuscular fat grafting retention by reducing muscle movement, thereby enhancing angiogenesis and adipogenesis. MATERIALS AND METHODS Pre-BTX+ nude mice were injected with BoNTA on the right quadriceps femoris and underwent supramuscular fat grafting 1 week later. BTX+ nude mice simultaneously underwent BoNTA injection and transplantation. Control nude mice underwent transplantation without BoNTA. Graft volumes were determined, and grafts underwent histological analyses and immunostaining. CatWalk XT gait analysis was conducted on BTX+ mice. RESULTS Pre-BTX+ and BTX+ groups had significantly higher retention rates and exhibited better angiogenesis and adipocyte survival than the Control group. CONCLUSION BoNTA injections improved the long-term retention of supramuscular fat grafts by reducing muscle movement, possibly by augmenting angiogenesis and adipogenesis. Address correspondence and reprint requests to: Ziqing Dong, MD, PhD, Department of Plastic and Cosmetic Surgery, Nanfang Hospital, Southern Medical University, 1838 Guangzhou North Road, Guangzhou, Guangdong 510515, People's Republic of China, or e-mail: doctordongziqing@hotmail.com Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.dermatologicsurgery.org). Supported by the National Nature Science Foundation of China (81772101, 81871573, 81801933, and 81601702). The authors have indicated no significant interest with commercial supporters. M. Wu and Y. Li contributed equally and are co-first authors. F. Lu and Z. Dong are co-corresponding authors. © 2019 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.

Mechanism of Action of Topical Garlic on Wound Healing

The Perialar Crescentic Advancement Flap: A Workhorse Flap for Small–Medium Size Defects of the Upper Cutaneous Lip

Reports of Potential Botulinum Toxin Spread in Inflamed Tissue

Teledermatology as a Tool for Preoperative Consultation Before Mohs Micrographic Surgery Within the Veterans Health Administration BACKGROUND Telemedicine is improving access to subspecialty care within the Veterans Health Administration (VHA). Mohs micrographic surgery (MMS) is a surgical modality used to treat nonmelanoma skin cancers. OBJECTIVE This study evaluates the use of teledermatology for preoperative consultation for MMS. METHODS AND MATERIALS A retrospective analysis of interfacility MMS referrals to the Bronx Veterans Affairs Medical Center (VAMC) was conducted. The consult failure rates (CFRs), treatment follow-through rates, time to treatment, and travel savings for “face-to-face” preoperative consults were compared with store-and-forward “teledermatology” preoperative consults. RESULTS Although both “teledermatology” and “face-to-face” preoperative consults resulted in an equivalent percentage of treated lesions, teledermatology had a significantly decreased CFR. In addition, teledermatology decreased the time to treatment by 2 weeks, increased the percentage of lesions treated within 60 days, and resulted in average travel savings of 162.7 minutes, 144.5 miles, and $60.00 per person. CONCLUSION This study demonstrates that teleconsultation is effective for preoperative consults for MMS within the VHA system. Teledermatology improved access measures such as time to treatment and travel burden. This program may serve as a model not only for other VAMCs that accept interfacility MMS consults, but also for VAMCs that provide other types of access-limited subspecialty care. Address correspondence and reprint requests to: Steven Lee, BS, Suite 2F, 130 W Kingsbridge Road, Bronx, NY 10468, or e-mail: skl2159@cumc.columbia.edu The authors have indicated no significant interest with commercial supporters. © 2019 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.

Emerging Nonsteroid-Based Procedural Therapies for Alopecia Areata: A Systematic Review BACKGROUND Alopecia areata (AA) is a common form of patchy, nonscarring hair loss. Although intralesional steroid injections are currently the mainstay procedural therapy for AA, other nonsteroid-based procedural therapies, including platelet-rich plasma (PRP), ultraviolet radiation (UVR), and laser-based modalities, are emerging as practical options. OBJECTIVE To systematically review nonsteroid-based procedural therapies for AA and recapitulate the available clinical data. MATERIALS AND METHODS A systematic review of the literature was performed searching PubMed/MEDLINE databases identifying studies investigating PRP, UVR, and laser-based modalities for AA treatment. RESULTS Literature search yielded 644 articles encompassing PRP, UVR, and laser treatment modalities for AA. Of the 644 articles, 46 met inclusion criteria. Although numerous reports demonstrate strong potential for PRP, UVR, and laser modalities in treating AA, high-quality evidence supporting their efficacy is still lacking. CONCLUSION There is an abundance of evidence for nonsteroid-based procedural therapies in the treatment of AA. Randomized control trials comparing these treatment options head-to-head should be performed to better understand the true efficacy of these treatments. Address correspondence and reprint requests to: Mark C. Marchitto, MD, 2150 Pennsylvania Avenue, NW Suite 2B-430, Washington, DC 20037, or e-mail: Marchitto@gwu.edu The authors have indicated no significant interest with commercial supporters. © 2019 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.